ceftolozane tazobactam (Zerbaxa)
Jump to navigation
Jump to search
Indications
- complicated urinary tract infections, including pyelonephritis
- complicated intra-abdominal infections combined with metronidazole
- multidrug-resistant Pseudomonas aeruginosa combined with colistin[2]
- hospital-acquired pneumonia; ventilator-associated pneumonia[3] (FDA-approved)
Contraindications
Dosage
- IV dosing every 8 hours
Antimicrobial activity
Adverse effects
- similar to other cephalosporins
- elevated liver enzyme levels, renal dysfunction, & diarrhea
Mechanism of action
- anti-pseudomonal cephalosorin with beta-lactamase inhibitor
- inhibits cell wall synthesis by binding penicillin-binding protein
- combined with beta-lactamase
More general terms
Components
References
- ↑ Zuger A The Newest Antibiotics on the Block. NEJM Journal Watch. June 13, 2016 Massachusetts Medical Society (subscription needed) http://www.jwatch.org
Deak D et al. Progress in the fight against multidrug-resistant bacteria? A review of U.S. Food and Drug Administration-approved antibiotics, 2010-2015. Ann Intern Med 2016 May 31 PMID: https://www.ncbi.nlm.nih.gov/pubmed/27239977 - ↑ Jump up to: 2.0 2.1 Medical Knowledge Self Assessment Program (MKSAP) 18, American College of Physicians, Philadelphia 2018
- ↑ Jump up to: 3.0 3.1 FDA News Release. June 3, 2019 FDA approves new treatment for hospital-acquired and ventilator- associated bacterial pneumonia. https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-hospital-acquired-and-ventilator-associated-bacterial-pneumonia